Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




HCV-RNA Present in Body Fluids in High Viral Load Patients

By LabMedica International staff writers
Posted on 26 Dec 2018
Hepatitis C virus (HCV) causes both acute and chronic infection. Acute HCV infection is usually asymptomatic, and is only very rarely (if ever) associated with life-threatening disease. About 15%–45% of infected persons spontaneously clear the virus within six months of infection without any treatment.

There is an ongoing epidemic of HCV) infection among men who have sex with men (MSM). Although epidemiological studies observed an association with certain sexual practices and/or concomitant recreational drug use, the underlying mechanisms of HCV transmission via these routes remains poorly defined.

Scientists at the Medical University of Vienna (Vienna, Austria) prospectively enrolled 34 Patients with acute (AHC) or chronic (CHC) HCV infection. Rectal and nasal swabs were obtained in all patients and after calibration and validation of the HCV assay, HCV-RNA levels were quantified in swab samples. Fecal occult blood tests were performed to rule out rectal bleeding. The mean age was 43 ± 8 years, the majority of patients (91%; 31/34) were HIV+ and 82% (28/34) were male of whom 64% (18/28) were MSM. Questionnaires were used to assess risk behavior related to recreational drug use and sexual practices.

AHC was observed in 32% (11/34) with all patients being HIV+MSM and 91% (10/11) having a history of sexually transmitted diseases. The most common HCV-genotype (GT) was GT-1a (50%; 17/34) whereas GT-1b, GT-2, GT-3 and GT-4 were observed in 15% (5/34), 3% (1/34), 21% (7/34) and 12% (4/34), respectively. Twenty-three (68%) patients had at least one positive swab sample (56%; 19/34 nasal and 52%; 17/33 rectal), whereas blood contamination was never detected. Individuals with positive swab sample had significantly higher HCV-RNA viremia versus patients with negative swab sample (6.37 IQR 1.06 log IU/mL versus 4.76 IQR 2.54 log IU/mL.

The authors concluded that HCV-RNA is readily detectable in rectal (despite the absence of fecal occult blood) and nasal fluids in patients with AHC/CHC, independently of HIV status, duration of HCV infection or the suspected route of HCV acquisition. Thus, the data strongly suggest that sharing of nasal drug-sniffing 'tools' and unprotected anal intercourse represent high-risk practices for HCV transmission, especially in patients with high serum HCV-RNA levels.

David Chromy, MD, the lead author of the study, said, “We actually did expect to find HCV RNA in the body fluids of our patients. Still we aimed to carefully rule out contamination of rectal fluid by occult bleeding (as a potential confounder) by performing a respective test for occult fecal blood. These bodily fluids may serve as vectors for transmission, still we strongly believe that additional mucosal trauma and/or bleeding is necessary for transmitting HCV-RNA and thus, HCV infection.” The study was presented at the American Association for the Study of Liver Diseases (AASLD; Liver Meeting) in held November 9-13, 2018, in San Francisco, CA, USA.

Related Links:
Medical University of Vienna


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
New
Immunofluorescence Analyzer
MPQuanti
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.